Termination of Liquidity Provision Service
Faron Pharmaceuticals Ltd. has terminated its liquidity provision agreement with Lago Kapital Oy, effective June 5, 2026, believing current share liquidity is sufficient without this arrangement. This decision could impact trading dynamics and investor perception of the company's share availability.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | May 06, 2026 at 09:00:00 EEST |
Faron has terminated the liquidity providing agreement with Lago Kapital
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that it has terminated the liquidity provision agreement with Lago Kapital Oy, with the termination taking effect on 5 June 2026.
The Company estimates that the current liquidity of the shares in the Company is sufficient without additional liquidity providers.
About BEXMAB
About bexmarilimab
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.